Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Therapy Against Ischemic Injury

Author(s): Giacinta Guarini, Alda Huqi, Paola Capozza, Doralisa Morrone, Francesca Donati and Mario Marzilli

Affiliation: Cardiovascular Medicine Division, Cardio-Thoracic and Vascular Department, Via Paradisa 2, 56124 Pisa (Pi).

Keywords: Ischemia-reperfusion injury, no reflow, preconditioning, postconditioning, mPTP, RISK and SAFE pathways, mitochondria, ROS, adenosine.

Abstract:

The advent of reperfusion therapy constituted a historical change for the management of myocardial infarction (MI) patients. However, shortly after, experimental models recognized an intrinsic damage, related to reperfusion itself, which was termed as ischemiareperfusion injury (IRI). Clinical studies attribute IRI a significant burden of morbidity and mortality observed in patients undergoing successful epicardial reperfusion. Several mechanisms have been identified and, as many strategies, have been investigated to address the phenomenon. In this review we will discuss the current evidence for IRI, pharmacological and non-pharmacological preventive strategies adopted both in experimental models and in clinical practice. Finally, we will try to provide a critical appraisal to the lack of consistent benefit observed in translational medicine.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 19
ISSUE: 25
Page: [4597 - 4621]
Pages: 25
DOI: 10.2174/1381612811319250008